Publication

Article

Pharmacy Times

January 2014 The Aging Population
Volume80
Issue 1

Smoking After Cancer Diagnosis Increases Death Risk in Men

Men who continue to smoke after being diagnosed with cancer are significantly more likely to die than those who quit, according to a recent study conducted in China.

Men who continue to smoke after being diagnosed with cancer are significantly more likely to die than those who quit, according to a recent study conducted in China.

The study, published in the December 2013 issue of Cancer Epidemiology, Biomarkers & Prevention, evaluated the relationship between postdiagnosis smoking and the risk of all-cause mortality in 1632 men diagnosed with cancer. Data were collected from a large cohort study of men 45 to 64 years of age, starting between 1986 and 1989. Annual interviews were conducted to determine changes in smoking status.

Overall, 747 men were smokers at the time of their cancer diagnosis, and 336 continued to smoke occasionally, while 197 continued to smoke regularly after the diagnosis. Patients who continued to smoke after their diagnosis had a 59% increased risk of death compared with those who did not smoke after the diagnosis. This increased risk for death among postdiagnosis smokers varied depending on the type of cancer the men had; compared with patients who quit smoking, hazard ratios were 2.36 in patients with lung cancer, 1.63 with stomach cancer, 2.31 with colorectal cancer, and 2.95 with bladder cancer.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
Image Credit: © Krakenimages.com - stock.adobe.com